脉冲与非脉冲糖皮质激素治疗特发性肺纤维化急性加重:多中心随机临床试验(SAFER)
本研究为多中心随机开放标签试验,纳入100例特发性肺纤维化急性加重成人患者,比较静脉脉冲甲泼尼龙(10 mg/kg×3天)与非脉冲方案(1 mg/kg×7天)的短期生存。结果显示脉冲方案未降低28天死亡率(10.0% vs 14.6%)或90天死亡率(24.5% vs 29.8%),次要结局亦无显著差异。
要点
- 脉冲甲泼尼龙未改善AE-IPF患者28天或90天生存。
- 28天死亡率脉冲组10.0%,非脉冲组14.6%,差异无统计学意义。
- 90天死亡率两组分别为24.5%和29.8%,未见显著差异。
核心结论
- 在AE-IPF成人患者中,脉冲剂量甲泼尼龙相比非脉冲糖皮质激素方案未显示出改善28天或90天生存的优势。
研究设计与样本
- 随机、开放标签、多中心试验,在韩国8所大学医院开展,纳入100例AE-IPF成人患者,1:1分配至脉冲组(n=51)或非脉冲组(n=49)。
主要发现
- 脉冲组28天死亡率为10.0%,非脉冲组为14.6%,风险差-4.6个百分点(95%CI -18.8至9.1;P=0.549)。
- 脉冲组90天死亡率为24.5%,非脉冲组为29.8%,风险差-5.3个百分点(95%CI -23.1至12.6;P=0.648)。
- 以移植为竞争事件的Fine-Gray分析未显示90天死亡率差异,次要结局两组间无显著差异。
临床怎么用
- 对于AE-IPF患者,脉冲剂量甲泼尼龙并未较非脉冲方案带来短期生存获益,临床选择糖皮质激素方案时可参考此证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) has high short-term mortality, yet guidelines weakly recommend corticosteroids without defining dose or duration. Pulse-dose methylprednisolone is widely used despite minimal evidence. OBJECTIVES: To test the superiority of a pulse-dose corticosteroid regimen over a nonpulse regimen with respect to short-term survival in AE-IPF. METHODS: In this randomised, open-label, multicenter trial at eight South Korean university hospitals, adults with AE-IPF were assigned (1:1) to receive either intravenous pulse methylprednisolone (10 mg/kg for 3 days) or nonpulse regimen (1 mg/kg for 7 days), followed by protocolised tapering and maintenance low-dose prednisolone. Primary outcomes were all-cause mortality at 28 and 90 days. Secondary outcomes included intensive care unit admission, use of mechanical ventilation or extracorporeal membrane oxygenation, death or lung transplantation at 28 and 90 days, and adverse events. The trial was registered at ClinicalTrials.gov, NCT04996303. MEASUREMENTS AND MAIN RESULTS: From July 2021 to April 2024, 100 patients were randomised (pulse n = 51; nonpulse n = 49). The pulse regimen did not demonstrate lower 28-day mortality than the nonpulse regimen (10.0% vs. 14.6%; risk difference, -4.6 percentage points; 95% CI, -18.8 to 9.1; P = 0.549) or lower 90-day mortality (24.5% vs. 29.8%; risk difference, -5.3 percentage points; 95% CI, -23.1 to 12.6; P = 0.648). Treating transplantation as a competing event, Fine-Gray analysis did not demonstrate a difference in 90-day mortality. Secondary outcomes were not demonstrably different between groups. CONCLUSIONS: Among adults with AE-IPF, pulse-dose methylprednisolone did not demonstrate improved 28- or 90-day survival compared with a nonpulse corticosteroid regimen.
引用
- Kim H, Jang HJ, Kim SY, et al. Pulse versus Nonpulse Corticosteroid Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized Clinical Trial (SAFER). Am J Respir Crit Care Med. 2026. PMID: 42813947. doi:10.1093/ajrccm/aamag529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。